Ready for NNVC? Watch it now!

NNVC May Be the Hottest Stock Trading Amid the Coronavirus The world was flipped upside down in 2020 when COVID-19 hit. It prompted biotech and medical companies to scramble to find solutions. As the virus continues to spread and new strains are found that may not even be protected by vaccines, NanoViricides, Inc. (NNVC) could soon be lighting up on Wall Street with its broad-spectrum nanoviricide anti-coronavirus drug candidates! The Company has been developing pan-coronavirus broad-spectrum antiviral drug candidates for the treatment of infected persons with COVID-19 since the first news of the novel 2019-nCoV disease came out. Among its developments, NanoViricides, Inc. (NNVC) has developed NV-CoV-2-R, which is a drug candidate that encapsulates Gilead's drug remdesivir inside the NV-CoV-2 nanomicelles. NV-CoV-2-R is thus designed to attack both (1) the virus lifecycle outside the cells, and (2) the virus lifecycle inside the cells, enabling complete control of the infection. NV-CoV-2-R is expected to be a potential cure for the virus! This may be the best time to have the company on your radar as they recently announced that they believe they have sufficient funds for initial human clinical trials of at least one of its drug candidates. See why NNVC could be the biggest biotech secret trading on the NYSE! NNVC is Fighting COVID and Shaping the Future of the Biotech Industry NNVC Looks Poised to Outperform in 2021 as Coronavirus Continues! Biotech companies continue to be in the spotlight with the focus remaining on development of coronavirus vaccines, antibodies, and treatments to fight the pandemic. While companies like Moderna and Pfizer have vaccines now being administered with high efficacy rates, the phenomenon that viruses develop variants to escape vaccines and antibodies is well known. Of concern is the fact that a mutation that is thought to enable the virus to escape a number of current vaccines. NanoViricides, Inc. (NNVC) may have the solution and is creating special purpose nanomaterials for antiviral therapy! The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. NanoViricides, Inc. (NNVC) is currently pursuing two separate drug candidates for the treatment of COVID-19 patients: NV-CoV-2 and NV-CoV-2-R, which is made up of NV-CoV-2 with Gilead's remdesivir encapsulated in it. NV-CoV-2-R is expected to be a potential cure for the virus! The Company is now preparing to submit a pre-IND application to the US FDA with safety tolerability and effectiveness data to obtain guidance regarding human clinical trials. Moderna saw its shares run from $20 to nearly $200 last year and now the next stock to see explosive upside could be NNVC! See why NNVC may be the biggest biotech ground-floor story unfolding! Could This Biotech Stock Be a Bigger Winner Than Moderna? NanoViricides, Inc. (NNVC) May Change the World with its Treatment to Fight Viruses! One of the industries to come very alive in 2020 during the global health crisis was the biotech arena, helping Moderna skyrocket from under $20 to almost $200. Biotech stocks have been all the rage in the last year as a number of companies have aspired to end the coronavirus pandemic including NanoViricides, Inc. (NNVC), a global leader in the development of nanomedicine drugs against viruses. The company's anti-viral therapeutics, called "nanoviricides®" are designed to appear to the virus like the native host cell surface to which it binds. Since these binding sites for a given virus do not change despite mutations and other changes in the virus, the company believes their treatments will be broad-spectrum, i.e. effective against most if not all strains, types, or subtypes, of a given virus! NanoViricides, Inc. (NNVC) is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. The Business Research Company anticipates the global anti-viral drug market size reaching a value of $87.23 billion in 2025, and $130.12 billion in 2030. As viruses continue to ravage the world, this could be the hottest company to watch this year! Read on to find out why NNVC could become a game-changing leader in medical treatments! Our Exclusive Report On: [( NanoViricides, Inc. (NNVC) is a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform. Just when you think the health crisis may be getting better, a new variant of COVID-19 surfaces and threatens to make the pandemic a lot worse before it gets better. Even though there may be vaccines now, there is growing concern that these vaccines may not protect against new strains of the virus. This is why NanoViricides, Inc. (NNVC) is a company to pay very close attention to right now! Scientific breakthroughs with coronavirus have led to some companies seeing extraordinary gains in the market. Shares of Moderna, who now has a vaccine out, have gone from under $20 at the beginning of February of 2020 to nearly $200 a share now! NanoViricides, Inc. (NNVC) could be the next stock to see explosive upside! The company is now successfully advancing broad-spectrum nanoviricide anti-coronavirus drug candidates towards human clinical trials! NanoViricides, Inc. (NNVC) has been developing pan-coronavirus broad-spectrum antiviral drug candidates for the treatment of infected persons with COVID-19 since the first news of the novel 2019-nCoV disease came out. The Company's drug candidate NV-CoV-2 is a nanoviricide® that is designed to attack coronaviruses irrespective of the variant. This is important because variants that are less sensitive to vaccines and antibodies than the original strain are already in widespread circulation in various countries. In fact the South African variant lineage B1.351 has already been found in Connecticut in a patient with no known travel history!! NanoViricides, Inc. (NNVC) recently reported in a press release that NV-CoV-2 had successfully completed GLP core safety pharmacology studies that are required prior to filing an IND and was found to be safe and well tolerated. In addition, the Company has developed NV-CoV-2-R, which is a drug candidate that encapsulates (holds in its "belly") remdesivir inside the NV-CoV-2 nanomicelles. NV-CoV-2-R is thus designed to attack both (1) the virus lifecycle outside the cells, and (2) the virus lifecycle inside the cells, enabling complete control of the infection. Therefore NV-CoV-2-R is expected to be a potential cure for the virus! The Company is preparing to submit a pre-IND application to the US FDA with safety tolerability and effectiveness data to obtain guidance regarding human clinical trials. Additionally, NanoViricides, Inc. (NNVC) is actively seeking opportunities to engage appropriate sites for human clinical trials. Further, the Company is engaged in the preparation of clinical trial protocols and other activities that would be necessary for submitting an IND application to the US FDA. The need for the broad-spectrum, pan-coronavirus nanoviricide drug treatments CANNOT be overstated for combating the COVID-19 pandemic given the current circumstances and the present status of the pandemic. New virus variants continue to develop in the field. The variants that have advantages in terms of transmissibility, infectivity, and escape from drugs and vaccines will continue to evolve and spread, replacing prior variants, especially under pressure of the use of vaccines and antibodies! The phenomenon that viruses develop variants to escape vaccines and antibodies is well known. Of concern is the fact that a mutation that is thought to enable the virus to escape a number of current vaccines, E484K, already present in the South African variant B1.351, and the Brazilian variant P.1, has spontaneously and independently arisen sporadically within the B1.1.7 UK-Kent variant. At present, B.1.1.7 is spreading in the USA, and is projected to become the dominant variant soon. B1.351 has also been found in the USA. The available monoclonal antibody drugs and convalescent plasma antibodies have been reported to be less effective against several variants compared to the original target strain. By the very nature of how they work, vaccines and antibodies tend to be highly specific to the target virus variant, and do not afford strong protection against differentiated variants that are evolutionarily distant from the target variant. This scientific fact is now well demonstrated for the COVID-19 pandemic. It is thus evident that effective broad-spectrum anti-coronavirus drugs such as NanoViricides, Inc. (NNVC)'s NV-CoV-2 and NV-CoV-2-R will be needed before the world can return to normal activity! NanoViricides, Inc. (NNVC) has developed NV-CoV-2 based on its platform nanoviricides® technology. This platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides, Inc. (NNVC) holds a worldwide exclusive perpetual license to this technology for several drugs. The Company has executed a Memorandum of Understanding with TheraCour that provides a limited license for research and development for drugs against human coronaviruses. The Company intends to obtain a full license and has begun the process for the same. This approach enables rapid development of new drugs against a number of different viruses. A nanoviricide is a "biomimetic" - it is designed to "look like" the cell surface to the virus. The nanoviricide technology enables direct attacks at multiple points on a virus particle. It is believed that such attacks would lead to the virus particle becoming ineffective at infecting cells. Antibodies in contrast attack a virus particle at only two attachment points per antibody. It is anticipated that when a virus comes in contact with the nanoviricide, not only would it land on the nanoviricide surface, binding to the copious number of ligands presented there, but it would also get entrapped because the nanomicelle polymer would turn around and fuse with the virus lipid envelope, harnessing a well known biophysical phenomenon called "lipid-lipid mixing". In a sense, a nanoviricide drug acts against viruses like a "venus-fly-trap" flower does against insects. Unlike antibodies that tag the virus and require the human immune system to take over and complete the task of dismantling the virus, a nanoviricide is a nanomachine that is designed to not only bind to the virus but also complete the task of rendering the virus particle ineffective. In addition, the company's nanoviricide technology also simultaneously enables attacking the rapid intracellular reproduction of the virus by incorporating one or more active pharmaceutical ingredients (APIs) within the core of the nanoviricide. NanoViricides, Inc. (NNVC)'s nanoviricide® technology is the ONLY technology in the world, to the best of the company's knowledge, that is capable of both (a) attacking extracellular virus, thereby breaking the reinfection cycle, and simultaneously (b) disrupting intracellular production of the virus, thereby enabling complete control of a virus infection. NanoViricides, Inc. (NNVC) has chosen to encapsulate "remdesivir," sponsored by Gilead, as the participating drug for blocking the viral replication cycle as the drug is approved by the US FDA for the treatment of SARS-CoV-2 infection. Encapsulation of remdesivir in the Company's nanoviricide envelope is expected to protect it from metabolism in the body. This protection can be expected to lead to significant enhancement in the effectiveness of remdesivir itself (in the encapsulated form), by potentially increasing both the effective remdesivir concentration and its duration of action. This could be an additional favorable effect for the Company's anti-coronavirus drug candidate NV-CoV-2-R. NanoViricides, Inc. (NNVC) is additionally developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. According to The Business Research Company, the global anti-viral drug market size reached a value of nearly $46.45 billion in 2019 and is expected to grow to $74.38 billion in 2023. The market is expected to reach $87.23 billion in 2025, and $130.12 billion in 2030. (Read more here: [( The coronavirus has been undoubtedly one of the biggest medical challenges of modern history. Despite this, there have been many coronavirus related stocks to offer opportunities to the savvy investor, even as fear spreads. Moderna is a great example as it saw its shares rise 800%+ over the past year! NanoViricides, Inc. (NNVC) could be the next big winner in the race to stop the pandemic and at current share prices could see immense upside! This could be one of the hottest stocks to be watching in 2021! Make sure you are ready to get all my alerts FAST by texting the word "Stocks" to "21000" (regular text messaging rates may apply) Also PLEASE take the time to read the following: ( I DO NOT MAKE ANY RECOMMENDATIONS TO BUY OR SELL ANY STOCKS, I JUST PROFILE COMPANIES AND YOU DECIDE WHAT TO DO) Placing a Trade First and foremost, you should always have streaming Level II quotes when trading. I honestly do not know how anyone trades without it! When trading, please follow the below guidelines: Always use a Limit Order: Most brokers won’t even allow you to use Market Orders. Limit Orders allow you to set the price that you want to buy and sell the stock at. This is common knowledge however, you may see some novice traders make the mistake of placing a market order to sell and take out all buyers at the bid, effectively overselling the stock to lower prices. Buy and Sell at the Ask: Many don’t realize that when you buy at the Ask price, you are HELPING the stock price to move up! Once that offer is gone from the shares you purchased, Market Makers could move up to the next offer price as they will see there are buyers at the current price. If you decide to place an order at the bid, you are basically hoping someone will sell their shares to you at this price and you may never get filled and miss the action. It is not always a bad idea to bid sit, as you are creating “bid support”, if you believe the price may come down again and you are not willing to buy higher. Using Stop Limit Orders: Some brokers do not allow you to use stops, however, if you can – it is always a good idea to set your stop loss at the lowest price you are willing to take a loss. You may kick yourself when the stock moves back up and your stop already executed, but remember, there will always be other opportunities and its always best to cut your losses just in case. All or None Orders (Fill or Kill): An example of an all or none order is when someone places an order to buy 100,000 shares @ .01 as an “all or none limit” order. By doing this they are telling the market that they wish to be filled on their entire position at .01 or not to be filled at all. For some reason we have seen market makers ignore these sort of orders on many occasions especially when a stock is on the move. We suggest against it but you will ultimately make the decision. Do Not Chase (ONE OF THE MOST IMPORTANT): Many people want to buy a stock so badly that they end up chasing the stock as it goes up. When they finally fill their order, they may have purchased it too high as traders who bought shares earlier begin to take profit, effectively lowering the stock price and making you a bag holder. Remember, 90% of the time, a stock will always retrace/dip back to an attractive level for you to grab shares. Stock Gaps: If a stock gaps up too high in pre-market, do Not Chase It. A big gap is typically 20-50% or more pre- market or within the first 5-10 minutes of the market opening. Most stocks that gap up will come down again during the day depending on what created the catalyst. Buying is always the catalyst but every once in a while there is earthshattering news on some of these small caps that makes pullbacks unlikely in the short term. Most of the time, when a stock gaps up the market makers will attempt to push it lower starting at this time to try to get investors to panic and sell shares back to them so they can make a profit on any shares they are short from filling orders on the gap. If you like the stock and it gaps up you can usually pick up cheaper shares when and if the market settles back. Sell Into Strength Not Weakness: Once you have taken a position in a stock you need to decide the price you would like to sell your shares. Most would recommend that you put a GTC sell order at that price. Unfortunately as traders have learned to utilize level 2, its best not to do submit GTC sell orders due to the possibility that your order will be represented by a market maker and it will seem as if there is resistance at that level which may compel sellers to get out of their position at a price lower than your price. We suggest that you watch the stock closely and once it hits your price target you can submit your order to sell. It’s important to understand that it’s always best to liquidate the stock into strength and preferably in smaller increments if you have a big position. There you have it!! These are ALL my biased, amateur and unlicensed opinions, should YOU choose freely, knowingly and intelligently to Play ANY of my featured play's!! (Please READ my statement below as well, it will help you understand how I benefit from this newsletter) Also always remember that every single alert I send is very volatile and risky. Any one of them could turn into a big loser. In my personal opinion, no matter how much potential any company has, 99% of the time all that matters is HOW THE STOCK TRADES. If a stock doesn’t trade well, nothing else matters. Don’t believe the hype. Be sure to use a tight stop, book profits quickly on these volatile trades, never let any one trade move too far against you, watch out for gaps, make sure the stock is trading in a healthy way before you enter, and monitor it closely to make sure momentum is positive. It’s always safest to book profits quickly, even on alerts with long-term potential. (Amateur biased unlicensed opinions) I would like to also explain how my Newsletter Makes MONEY!! I DON’T FRONTLOAD, BUY, RECEIVE any SHARES of a Company I Profile!! I NEVER OWN ANY POSITION IN A COMPANY I ALERT/PROFILE!! It would be UNFAIR, WRONG and ILLEGAL for me to have a position in ANY Company I ever Profile on my Newsletter! I am what is known as a STOCK PROMOTER!! I just wanted to address this issue for some people who might think I trade the companies I profile on my Newsletter or I own a position before or during the time I profile them!!! The honest truth is I DO NOT!!….. I do get CASH compensation to profile companies most of the times I talk about them in my Newsletter, this is HOW I MAKE MONEY and pretty much how 99% of ALL the other Newsletters out there make money…… Most of you have signed up to my Newsletter because of an advertisement you saw, well it costs money to run those advertisements…. I ALWAYS Disclose how much and who paid me in my Disclaimer at the end of each e-mail!!! Here is some information directly from the SEC Website: Tips for Checking Out Newsletters “Find out whether the newsletter received payment to “tout” or recommend the stock and, if so, what it received and from whom. Because the U.S. Constitution’s First Amendment protects freedom of speech, the SEC cannot simply prohibit newsletters from recommending or touting particular stocks. But when newsletters receive payment for touting, the securities laws require them to disclose specifically who paid them, the amount, and the type of payment (cash, stock, or some other thing of value). Read carefully what the newsletter says about payments it receives. Be suspicious of newsletters that do not specifically disclose these items: who paid them, the amount, and the type of payment. The following examples raise red flags because they do not contain specific information: “From time to time, XYZ Newsletter may receive compensation from companies we write about.” “From time to time, XYZ Newsletter or its officers, directors, or staff may hold stock in some of the companies we write about.” “XYZ Newsletter receives fees from the companies we write about in our newsletter.” Think twice about newsletters that bury their disclosures or put them in tiny, hard-to-read typeface. Legitimate online newsletters that have been paid to tout stocks will clearly and specifically tell investors who paid them, the amount, and the type of payment. Look for their disclosure statements in articles about particular companies or in a list or chart on their websites.” I hope this answers a lot of your questions and also gives you a better perspective to my play’s the Next Time you see one!! Don’t forget to tell everyone you know about PTE.la and help my Newsletter Grow!! Remember to trade smart, research your options, and use due diligence! Sincerely, PTE.la © 2020 PTE.la PTE, LLC (publisher of PTE.la) is NOT registered as an investment adviser nor a broker/dealer with either the U. S. Securities & Exchange Commission or any state securities regulatory authority. Users of this website are advised that all information presented on this website is solely for informational purposes, is not intended to be used as a personalized investment recommendation, and is not attuned to any specific portfolio or to any user's particular investment needs or objectives. Past performance is NOT indicative of future results. Furthermore, such information is not to be construed as an offer to sell or the solicitation of an offer to buy, nor is it to be construed as a recommendation to buy, hold or sell (short or otherwise) any security. All users of this website must determine for themselves what specific investments to make or not make and are urged to consult with their own independent financial advisors with respect to any investment decision. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. All opinions, analyses and information included on this website are based on sources believed to be reliable and written in good faith, but should be independently verified, and no representation or warranty of any kind, express or implied, is made, including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. In addition, we undertake no responsibility to notify such opinions, analyses or information or to keep such opinions, analyses or information current. Also be aware that owners, employees and writers of and for PTE, LLC may have long or short positions in securities that may be discussed on this website or newsletter. Past results are not indicative of future profits. This table is accurate, though not every trade is represented. Profits and losses reported are simulated figures from virtual simulated portfolios. We are engaged in the business of advertising and promoting companies for monetary compensation. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Neither the information presented nor any statement or expression of opinion, or any other matter herein, directly or indirectly constitutes a solicitation of the purchase or sale of any securities. PTE.la’s sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by PTE.la or an offer or solicitation to buy or sell any security. Neither the owner of PTE.la nor any of its members, officers, directors, contractors or employees is licensed broker-dealers, account representatives, market makers, investment bankers, investment advisors, analyst or underwriters. Investing in securities, including the securities of those companies profiled or discussed on this website is for individuals tolerant of high risks. Viewers should always consult with alicensed securities professional before purchasing or selling any securities of companies profiled or discussed in our releases. It is possible that a viewer’s entire investment may be lost or impaired due to the speculative nature of the companies profiled. Remember, never invest in any security of a company profiled or discussed in a release or on our website unless you can afford to lose your entire investment. Also, investing in micro-cap securities is highly speculative and carries an extremely high degree of risk. To review our complete disclaimer and additional information, please visit . PTE.la makes no recommendation that the securities of the companies profiled or discussed in our releases or on our website should be purchased, sold or held by investors. PTE.la is owned and operated by PTE LLC. PTE LLC has been compensated up to Twenty-Five Thousand Dollars Cash by a third party ACN LLC to conduct investor relations advertising and marketing for NNVC . Any compensation received by PTE LLC constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. A third party of PTE LLC may have shares and may liquidate, which may negatively affect the stock price. PTE LLC affiliates may at any time have a position in the securities mentioned herein and may increase or decrease such positions without notice which will negatively affect the market. Some of the content in this release contains forward - looking information within the meaning of Section 27 A of the Securities Act of 1 9 9 3 and Section 21 E of the Securities Exchange Act of 1 9 3 4 including statements regarding expected continual growth of the profiled company and the value of its securities. In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 it is hereby noted that statements contained herein that look forward in time which include everything other than historical information, involve risk and uncertainties that may affect a company's actual results of operation. A company's actual performance could greatly differ from those described in any forward - looking statements or announcements mentioned in this release. Factors that should be considered that could cause actual results to differ include: the size and growth of the market for the company's products; the company's ability to fund its capital requirements in the near term and in the long term; pricing pressures; unforeseen and/or unexpected circumstances in happenings; etc. and the risk factors and other factors set forth in the company’s filings with the Securities and Exchange Commission. However, acompany’s past performance does not guarantee future results. Generally, the information regarding a company profiled is provided from public sources which we believe to be reliable but is not guaranteed by us as being accurate. Further specific financial information, filings and disclosures as well as general investor information about the profiled company, advice to investors and other investor resources are available at the Securities and Exchange Commission (“SEC”) website www.sec.gov and the Financial Industry Regulatory Authority (“FINRA”) website at www.finra.org. Any investment should be made only after consulting with a qualified investment advisor and reviewing the publicly available financial statement and other information about the company profiled and verifying that the investment is appropriate and suitable. PTE.la makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. Viewers should not rely solely on the information obtained in this release or on our website. PTE Team 9 Downing street Newark NJ 07105 USA [Unsubscribe]( [Change subscriber options](